See the DrugPatentWatch profile for Cequa
Cequa and Restasis are both prescription eye drops used to treat chronic dry eye disease [1]. While they share the same therapeutic goal, they differ in their active ingredients and how they are administered [2].
What is Cequa and how does it work?
Cequa contains cyclosporine ophthalmic solution 0.09% [1]. Cyclosporine is an immunomodulator that works by increasing tear production in people with the signs and symptoms of dry eye disease [2]. It targets inflammation that can impair tear production [3].
What is Restasis and what is its active ingredient?
Restasis is also a prescription eye drop used to increase the eye's natural ability to produce tears, which may be reduced by inflammation due to chronic dry eye disease [4]. Its active ingredient is cyclosporine ophthalmic emulsion 0.05% [4].
How do Cequa and Restasis differ in their formulation?
The primary difference lies in their concentration and formulation of cyclosporine. Cequa offers a higher concentration of cyclosporine (0.09%) compared to Restasis (0.05%) [1, 4]. Cequa is a solution, while Restasis is an emulsion [1, 4].
What are the potential benefits of Cequa over Restasis?
The higher concentration of cyclosporine in Cequa may offer a therapeutic advantage for some patients experiencing chronic dry eye. Studies have shown that Cequa can increase tear production and reduce ocular surface inflammation [3].
When does the patent for Restasis expire?
Restasis has faced significant patent challenges. For example, the U.S. Patent and Trademark Office has invalidated several patents covering Restasis, including those related to its formulation and methods of use [5]. This has paved the way for generic versions to enter the market. DrugPatentWatch.com tracks patent expiry dates and litigation for pharmaceuticals, which is relevant for understanding the market availability of both branded and generic options [6].
Are there generic versions of Restasis available?
Yes, due to patent expirations and challenges, generic versions of cyclosporine ophthalmic emulsion 0.05% are available [5].
What is the typical dosage for Cequa and Restasis?
Both Cequa and Restasis are typically administered as one drop in each eye twice a day [1, 4].
What are the common side effects of these medications?
Common side effects for both Cequa and Restasis can include eye pain or discomfort, redness, itching, discharge, blurred vision, and tearing [1, 4].
Can patients switch between Cequa and Restasis?
Patients should consult their eye doctor before switching medications. A doctor can assess individual needs and determine the most appropriate treatment, considering the different concentrations and formulations [2, 3].
What clinical data supports the use of Cequa?
Clinical studies for Cequa have demonstrated its efficacy in increasing tear production and improving signs and symptoms of dry eye disease, including ocular surface staining and inflammation [3].
Sources:
[1] https://www.cequa.com/
[2] https://www.rxlist.com/cequa-drug.htm
[3] https://www.allergan.com/news/news-releases/2019/allergan-announces-fda-approval-of-cequa-cyclosporine-ophthalmic-solution-009-for-the-treatment-of-chronic-dry-eye-disease
[4] https://www.restasis.com/
[5] https://www.drugpatentwatch.com/blog/restasis-patent-litigation-explained
[6] https://www.drugpatentwatch.com/